CD274 and non-small cell lung carcinoma: Following, the rationale of ICI treatment with Pembrolizumab was to prevent systemic and local disease progression; FDA and EMA have approved Pembrolizumab as first line treatment in patients with advanced NSCLC and PD-L1 strong expression, as the present, based on the results of KEYNOTE-024 study [5].